J Thromb Haemost: Recombinant human soluble thrombosis-regulated protein sepsis efficacy and safety in patients with sepsis-related clotting disorders

The efficacy and safety of the recombinant human soluble thrombosis-regulated protein (rhsTM) has not been clearly proven and its effects may depend on the presence or absence of sepsis-related clotting disease (SAC)Recently, the authoritative journal Journal of Thrombosis and Haemostasis published a research article, the system evaluation and meta-analysis is designed to assess the efficacy and safety of rhsTM in SAC patients, sAC is determined by high international standardization rates and low platelet countsresearchers searched the EMBASE, MEDLINE, CENTRAL, and Clinicaltrial.gov databases to determine a randomized controlled trial (RCT) comparing rhsTM with patients with placebo or untreated sepsisThe outcome was 28 days of mortality and the safe outcome was hemorrhageresearchers included three RCTs and 1,633 patientsPatients with SAC had a higher 28-day mortality rate (risk ratio of 1.32; 95% confidence interval (CI) 1.06-1.64 compared to patients without SACRhsTM treatment significantly reduced the patient's mortality rate by 28 days compared to patients with placebo or untreated SAC (RR 0.80; 95% CI is 0.65-0.98), but for patients without SAC (RR 1.17; 95% CI is 0.82-1.67) or the entire study population (RR is 0.88; 95% CI is 0.74-1.04) no significant effectThe whole population (RR is 1.25; 95% CI is 0.80-1.96), SAC patients (RR is 0.94; 95% CI is 0.45-1.95) and patients without SAC (RR 2.26; In 95% CI was 0.95-5.35), there was no significant difference in the incidence of haemorrhage between rhsTM and the control drug, sAC is associated with a higher 28-day mortality rate in patients with sepsisThe use of rhsTM reduced the 28-day mortality rate in SAC patients, but did not reduce the mortality rate in patients without SAC